A method of updating the status of an insurance customer includes identifying a plurality of individuals with a first insurance status and delivering home testing kits to the plurality of individuals. Upon completion of the home testing kits, medical image information is received from a mobile communications device and processed to determine a state of a medical analysis region. Individuals with medical analysis regions in a differing state of criticality are identified. Healthcare providers may be provided with information indicating that there is a likelihood that the identified individuals are entitled to a second insurance status.

A method for designing and monitoring a fasting and lifestyle regimen for a individual can include: a) diagnosing the individual by a series of questions and physical measurements to determine a test profile; b) determining one or more goals to achieve balance by analyzing the test profile of the individual or by accepting direct input of the individual; and c) determining a fasting and lifestyle regimen for the individual by algorithmic mapping of the test profile and one or more goals that can help achieve balance and growth. Test strips for analyzing body fluid are also disclosed, as are methods of use of the test strips. An application for implementing the methods is also disclosed.

A biometric system is disclosed. The biometric system comprises: a measurement cartridge; and a meter, equipped with the measurement cartridge, for measuring an analyte present in a sample of the measurement cartridge. The measurement cartridge comprises a reagent container, a capillary module, and a reagent rod. The reagent container receives a liquid reagent and has a top sealed with a sealing film. The capillary module comprises a capillary tube which is located on an upper side of the reagent container and collects the sample by a capillary phenomenon, and the capillary tube is introduced into the reagent container by rupturing a contact portion to the sealing film by an applied pressure. The reagent rod comprises a plurality of dry reagent accommodating portions which are located on an upper side of the reagent container and accommodate a drying reagent, and the reagent rod is introduced into the reagent container by rupturing a contact portion to the sealing film by an applied pressure.

A method of quantitatively determining the concentration of at least one analyte in a sample by: (i) adding a portion of the sample to a first analyte assay formulation and to an analyte assay reference formulation to generate a first analyte sample and analyte reference sample and determining the concentration of the at least one analyte in the sample; and/or (ii) adding a portion of the sample to a second analyte assay formulation and determining the concentration of the at least one analyte in the sample, as well as formulations, kits of parts, systems and computer implemented methods associated with the method.

An in vitro method for diagnosing Alzheimer's disease (AD) includes determining the content of mercaptoalbumin (HMA) in a sample of cerebrospinal fluid (CSF), and comparing the content determined with the content of HMA in CSF in healthy subjects. If the HMA content is less than that of the healthy subjects, it is indicative of AD.

The present invention provides a method, wherein the method classifies a subject as suffering from dry eye, the method consisting of: a. obtaining demographic data, consisting of the age and gender of the subject; b. obtaining a tear sample from the patient, and determining the level of human serum albumin; c. from the determined level of human serum albumin, assigning a score for the determined amount of human serum albumin; and d. from the assigned score, calculating a cutoff probability score, according to the following equation:

[00001]$\frac{\exp \left(-0.6491-1.1142*\mathrm{Albumin}\right)}{1+\exp \left(-0.6491-1.1142*\mathrm{Albumin}\right)}$

wherein the subject has dry eye, if the calculated cutoff probability score is from 50% to 60%.

The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.

A urinalysis device for non-clinical use is provided, the device comprising: a housing; a touchscreen on the housing; a test strip holder, which is removably, slidably engaged with the housing; at least two light emitting diode (LED) light sources, housed in the housing and including a white LED and a red-blue-green (RBG) LED; a camera module housed in the housing, both the plurality of LEDs and the camera module directed to an illumination and detection zone; a timer system; and a computational system, the computational system in electronic communication with the plurality of LEDs, the camera module and the timer system, the computational system including a processor and a memory.

The present invention includes methods for treating, preventing, or assessing the levels of risk for acute kidney injury (AKI) in a subject via measuring concentrations of tumor necrosis factor receptor-1 (TNFR1), tumor necrosis factor receptor-2 (TNFR2), and kidney injury molecule-1 (KIM-1).

Systems and methods are provided for sample processing. A device may be provided, capable of receiving the sample, and performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing multiple assays. The device may comprise one or more modules that may be capable of performing one or more of a sample preparation, sample assay, and detection step. The device may be capable of performing the steps using a small volume of sample.